AI Terminal
ALLERGY THERAPEUTICS PLC
Director's Dealing • Nov 11, 2021
7477_dirs_2021-11-11_f9a653c9-eac7-4efc-a937-fdf49cf13d50.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0193S
Allergy Therapeutics PLC
11 November 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Director Dealings
11 November 2021 - Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that Peter Jensen, Non-Executive Chairman, has purchased 30,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at a price of 36 pence per Ordinary Share. Following the transaction, the total beneficial interest of Peter Jensen is 300,000 Ordinary Shares, representing 0.05% of the of the issued share capital of the Company to which voting rights are attached.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott, David Daley, Davide Salvi, Alex Gunter
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Peter Jensen
2
Reason for the notification
a)
Position/status
Non-Executive Chairman, Director
b)
Initial notification/Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Allergy Therapeutics plc
b)
LEI
213800PQ7AHK7KGVOE23
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
0.1p ordinary shares
GB00B02LCQ05
b)
Nature of the transaction
Purchase of Ordinary Shares
c)
Price(s) and volume(s)
| Price(s) per Ordinary Share | Volume(s) |
| 36 pence | 30,000 |
d)
Aggregated information
N/A
e)
Date of the transaction
10 November 2021
f)
Place of the transaction
London Stock Exchange - AIM
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHMZMMMMGZGMZZ